Last reviewed · How we verify
CC312
At a glance
| Generic name | CC312 |
|---|---|
| Sponsor | CytoCares Inc |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of CC312 for Relapsed/Refractory Autoimmune Diseases (EARLY_PHASE1)
- Safety Study of CC312 in Adult Patients With Relapsed/Refractory CD19 Positive B-cell Hematologic Malignancies (PHASE1)
- Safety and Efficacy Study of CC312 for Moderate to Severe SLE (PHASE1)
- Safety Study of CC312 in Autoimmune Disease Patients (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |